Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 79 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Importance of achieving the composite endpoints in diabetes

Unnikrishnan Ambika Gopalakrishnan, Bhattacharyya Arpandev, Baruah Manash Pratim, Sinha Binayak, Dharmalingam Mala, Rao Paturi V

Year : 2013| Volume: 17| Issue : 5 | Page no: 835-843

   This article has been cited by
1 Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
Fumika Shigiyama,Naoki Kumashiro,Ayako Fuchigami,Takahisa Hirose
Cardiovascular Diabetology. 2018; 17(1)
[Pubmed]  [Google Scholar] [DOI]
2 Simultaneous inference of a binary composite endpoint and its components
M. Große Ruse,C. Ritz,L.A. Hothorn
Journal of Biopharmaceutical Statistics. 2016;
[Pubmed]  [Google Scholar] [DOI]
3 Proceedings From FDA/A.S.P.E.N. Public Workshop
Daniel H. Teitelbaum,Peggi Guenter,Donna Griebel,Steven A. Abrams,Staffan Bark,Mary Baker,Karyn L. Berry,Bruce R. Bistrian,J. Thomas Brenna,Denis Bonnot,Yvon A. Carpentier,Richard J. Deckelbaum,Mary Hise,Berthold Koletzko,Jay M. Mirtallo,Andrew E. Mulberg,Randall C. O’Reilly,Jonathan Shaffer,Elke von Kleist,Gary P. Zaloga,Thomas R. Ziegler
Journal of Parenteral and Enteral Nutrition. 2015; 39(7): 768
[Pubmed]  [Google Scholar] [DOI]
4 A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes
Stuart A. Ross
Current Medical Research and Opinion. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]


Read this article